Cervical Conization of Adenocarcinoma in Situ: a Predicting Model of Residual Disease
Overview
Authors
Affiliations
Objective: To determine factors associated with the presence of residual disease in women who have undergone cervical conization for adenocarcinoma in situ (ACIS) of the cervix.
Study Design: We identified women who underwent a cervical conization for a diagnosis of ACIS followed by repeat conization or hysterectomy between Jan. 1, 1995, and April 30, 2010. Data were summarized using standard descriptive statistics.
Results: Seventy-eight patients met study criteria. The presence of ACIS at the internal conization margin or in the postconization endocervical curettage (ECC) correlated with residual ACIS (P < .001). A margin positive for ACIS was associated with residual glandular neoplasia in 68% of cases. An endocervical curettage positive for ACIS was associated with residual ACIS in 95% of cases. If both the margins and the endocervical curettage were positive for the presence of ACIS, 8% did not have residual disease, 77% had residual ACIS, and 15% had invasive adenocarcinoma. If both the internal conization margin and the postconization ECC were negative for the presence of ACIS, 14% of the final specimens had residual ACIS and none had invasive cancer.
Conclusion: The addition of postconization ECC to cone biopsy for ACIS of the cervix provides valuable prognostic information regarding the risk of residual ACIS. Women with ACIS who have both a negative postconization ECC and a negative conization margin have a 14% risk for residual ACIS and can be treated conservatively if desiring fertility. A positive postconization ECC or internal margin incurs significant risk of residual disease and 12-17% will have cancer.
ECC at LLETZ-An Exploratory Retrospective Cohort Study.
Paternostro C, Joura E, Ott J, Ghobrial S, Langthaler E, Pils S J Clin Med. 2024; 13(22).
PMID: 39597815 PMC: 11594823. DOI: 10.3390/jcm13226671.
Utilization of lymph node evaluation at hysterectomy for cervical carcinoma in situ.
Matsuo K, Tavakoli A, Donovan K, Mandelbaum R, Klar M, Roman L J Surg Oncol. 2022; 126(8):1543-1550.
PMID: 36036713 PMC: 9804672. DOI: 10.1002/jso.27069.
Hong L, Huynh S, Kim J, Denham L, Momeni M, Ioffe Y Diagnostics (Basel). 2021; 11(10).
PMID: 34679587 PMC: 8534706. DOI: 10.3390/diagnostics11101889.
Du W, Wang Y, Li D, Xia X, Tan Q, Xiong X Front Oncol. 2021; 11:637794.
PMID: 34322375 PMC: 8311659. DOI: 10.3389/fonc.2021.637794.
Wang X, Bi Y, Wu H, Wu M, Li L Sci Rep. 2020; 10(1):19920.
PMID: 33199765 PMC: 7669853. DOI: 10.1038/s41598-020-75512-9.